Treating Adult Patients with Growth Hormone Deficiency: Diagnostic Tools and New Treatment Options for Optimal Health


Kevin C.J. Yuen, MD, FRCP (UK), FACE
Medical Director of Barrow Pituitary Center Barrow Neurological Institute
Professor of Medicine University of Arizona College of Medicine and Creighton School of Medicine Phoenix, AZ
Kevin C.J. Yuen, MD, FRCP (UK), FACE

Dr. Kevin CJ Yuen is a Professor of Medicine at the University of Arizona College of Medicine and Creighton School of Medicine, as well as the Medical Director of both the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic at the Barrow Neurological Institute, located in Phoenix, AZ. The focus of his clinical practice is on the diagnosis and treatment of pituitary and adrenal disorders, with a particular interest in growth hormone deficiency and excess, and cortisol deficiency and excess.

Dr. Yuen earned his bachelor’s degree in Medicine and Surgery at the University of Sheffield, United Kingdom. He trained in Internal Medicine at the University of Southampton and completed his clinical fellowship in Endocrinology at the University of Cambridge, where he spent an additional 2 years in an advanced neuroendocrinology research training program before completing 3 years of postdoctoral research and advanced clinical neuroendocrinology training at the Oregon Health and Science University in Portland, OR.

Dr. Yuen is the lead educator for the Pituitary section of the Fellowship program at his institution, and has conducted many growth hormone dosing and diagnostic studies, long-acting growth hormone formulation studies, and trials with new drug therapies for acromegaly and Cushing syndrome. He has published extensively, authored book chapters, and is a frequent guest speaker on various topics related to pituitary disorders. Dr. Yuen serves on several national and international committees and advisory boards on pituitary diseases. He is the current Editor-in-Chief of the Growth Hormone and IGF Research journal, and is also on the editorial boards of several other Endocrinology journals. He is currently actively involved as the Principal Investigator in several clinical research studies involving diagnostic and medical treatments for acromegaly, Cushing syndrome and long-acting growth hormone preparations.

Mark E. Molitch, MD
Professor Emeritus Division of Endocrinology, Metabolism and Molecular Medicine Northwestern University Feinberg School of Medicine Chicago, IL
Mark E. Molitch, MD

Mark E. Molitch, MD, is Professor Emeritus in the Division of Endocrinology, Metabolism, and Molecular Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. His research has focused on the pathogenesis and treatment of pituitary tumors and the effects of such tumors on pregnancy.

Julie M. Silverstein, MD
Medical Director Pituitary Center
Associate Professor of Medicine and Neurological Surgery, Division of Endocrinology, Metabolism and Lipid Research
Washington University School of Medicine, St. Louis, MO
Julie M. Silverstein, MD

Julie Silverstein MD is Associate Professor of Medicine & Neurological Surgery and Medical Director of the Pituitary Center at Washington University School of Medicine in St. Louis, MO. She completed a residency in Internal Medicine at the University of Pittsburgh in the women’s health track in 2007 and completed her fellowship in Endocrinology at Washington University School of Medicine in 2009. She currently oversees the medical management of patients with pituitary disorders and related diseases both in the outpatient and inpatient settings. Her research interests include the perioperative care of patients undergoing surgery for pituitary tumors and she has conducted clinical trials investigating the management of steroids and fluids after transsphenoidal resection of pituitary tumors. She is also involved in clinical trials investigating medical therapies for patients with acromegaly, Cushing’s disease and other types of pituitary problems.

Statement of Need

The clinical management of adult growth hormone deficiency (GHD) comprises caring for patients who are transitioning from pediatric to adult services, as well as patients with adult-onset (AO) GHD. There are unique challenges and opportunities in both scenarios, including who and when to test, which diagnostic tests to use, consideration of current and emerging treatment strategies, and improving patient adherence to therapies. The “art of medicine” and shared decision-making play important roles in GHD – as both medical and psychological factors need to be addressed to optimize outcomes.

In this OnDemand CMEO symposium, three experts in GHD follow the patient journeys of a young adult transitioning from pediatric care and a 50-year-old patient with AO-GHD. Clinical application of guidelines, a review of key study results, and the role of long-acting growth hormone preparations will be discussed.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Incorporate evidence-based diagnostic testing to achieve a prompt and accurate diagnosis in individuals with GHD.
  • Outline the clinical challenges associated with the management of GHD.
  • Evaluate the current and emerging treatment strategies for the management of GHD.

Financial Support

Supported by an educational grant from Novo Nordisk, Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in endocrinology.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.0 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

California Residents

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit. Jump to Activity UAN.


CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Yuen reports the following financial relationships: Advisory Board: Amryt Pharma; Ascendis Pharma Group; Corcept; Crinetics; Ipsen Pharma; Novo Nordisk; Rani Therapeutics; Recordati; and Strongbridge Biopharma. Research Support: Grants paid to Barrow Neurological Institute: Amryt Pharma; Ascendis Pharma Group; Corcept; and Novartis

Dr. Molitch reports the following financial relationships: Advisory Board: Strongbridge Biopharma. Consultant: Amryt Pharma and Corcept

Dr. Silverstein reports the following financial relationships: Advisory Board: Chiasma, Inc.; Recordati S.p.A.; and Strongbridge Biopharma plc

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Warren Beckman (planning committee)

Kathleen Blake, PhD (planning committee)

Thomas Mitchell (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.



NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-082-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).



Treating Adult Patients with Growth Hormone Deficiency: Diagnostic Tools and New Treatment Options for Optimal Health
Event Date: 05/18/2022